Novo Nordisk sued telehealth firm Hims & Hers for alleged patent infringement over semaglutide (Wegovy), seeking damages it described as potentially in the 'hundreds of millions.' Novo accused Hims of mass‑marketing an unapproved, inauthentic semaglutide pill using an untested delivery mechanism that lacks FDA review. The FDA’s commissioner responded directly, warning that the agency will take swift action against companies mass‑marketing unapproved copycat drugs. The pair of legal and regulatory moves signal intensified enforcement around the fast‑growing GLP‑1 obesity market and could reshape telehealth compounding practices.